Sartorius AG and its biotech subsidiary lifted to Buy at Barclays By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2025
0mins
Source: Investing.com
Barclays Upgrade: Barclays has upgraded Sartorius AG and Sartorius Stedim Biotech to Overweight, citing a post-COVID recovery in the bioprocessing industry and significant valuation discounts compared to peers, indicating potential for upside as order momentum returns.
Growth Forecasts: Barclays forecasts approximately 12% growth in bioprocess solutions orders for Sartorius in FY25, with overall group sales expected to grow around 7.3%, supported by strong free cash flow generation and improved investor sentiment.
Analyst Views on SATG
Wall Street analysts forecast SATG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SATG is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 21.855
Low
Averages
High
Current: 21.855
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
